The NRBDO requests improved patient engagement in product reviews:
The NRBDO requests a review of the secondary restriction on the use of
Solvent Detergent Plasma (SDP):
Solvent Detergent Plasma (SDP):
- Letter to National Advisory Committee on Blood and Blood Products - October 2018
- Letter to the Prov./Terr. Blood Liaison Committee - February 2017
Other Advocacy Positions & Letters:
- Position Statement on Distribution of Fractionated products and their replacements (2019)
- Position Statement on Blood Product Distribution (2018)
- Position Statement on MSM Deferral Policies (updated 2018)
- Position Statement on a National Pharmacare Program
- PMPRB Guidelines Consultation Submission - February 2020
- Letter to federal party leaders - October 2019
- Letter to P/T MOH regarding consumer representatives on CBS board - March 2019
- Letter in support of a move from a 1-yr to 3-month MSM deferral by CBS - December 2018
- Letter to P/T Deputy Ministers of Health re: new blood product review process - June 2018
- Letter to Innovative Medicines Canada re: travel reimbursement for medical professionals - June 2018
- Questionnaire for Ontario Election Candidates - 2018
- Ontario Pre-budget Submission, advocating for Comprehensive Care - February 2018
- Letter to CADTH requesting Path for Patient Input in Blood Product Reviews - January 2018
- Letter to CADTH requesting Path for Patient Input in Blood Product Reviews - CBS cover - January 2018
- Letter to CBS regarding product tender process and outcomes, from CSACI and AMMI Canada, which the NRBDO also signed on to - December 2017
- Letter to the Federal Minister of Health in support of the Orphan Drug Framework - January 2016
- Letter in support of a move from a 5-yr to 1-yr MSM deferral by CBS - November 2015